Aerobid | 77326-96-6

• 物质功能分类: 医药中间体
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Aerobid
• 英文别名: (1S,2S,4R,8S,9S,11S,12S,13R,19S)-19-fluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one;hydrate
• CAS: 77326-96-6
• 化学式: C48H64F2O13
• 分子量: 887.0
• InChiKey: MIXMJCQRHVAJIO-TZHJZOAOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.72
• 重原子数：
  63
• 可旋转键数：
  4
• 环数：
  10.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  187
• 氢给体数：
  5
• 氢受体数：
  15

ADMET

毒理性

• 在妊娠和哺乳期间的影响

使用说明: 尽管没有测量，但吸入皮质类固醇进入母体血液和排入母乳的量可能太小，不会影响哺乳婴儿。审阅者和专家小组认为，在哺乳期间可以使用吸入和口服皮质类固醇。 对哺乳婴儿的影响: 截至修订日期，没有发现任何皮质类固醇对哺乳婴儿有影响。 对泌乳和母乳的影响: 截至修订日期，没有找到相关的已发布信息。

◉ Summary of Use during Lactation:Although not measured, the amounts of inhaled corticosteroids absorbed into the maternal bloodstream and excreted into breastmilk are probably too small to affect a breastfed infant. Reviewers and an expert panel consider inhaled and oral corticosteroids acceptable to use during breastfeeding. ◉ Effects in Breastfed Infants:None reported with any corticosteroid. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.

来源:Drugs and Lactation Database (LactMed)

制备方法与用途

氟尼缩松是一种皮质类固醇，主要用于治疗过敏性鼻炎，通常被认定为控制此类症状最为有效的药物之一。其主要作用机制在于激活糖皮质激素受体，从而发挥强大的抗炎效果。

文献信息

• PROCESS FOR THE PREPARATION OF FLUOROTETRAENE
  申请人：Ferrino Sergio

  公开号：US20080234506A1

  公开（公告）日：2008-09-25

  There is provided a process for preparing 21-acetyloxy-6-alpha-fluoro-pregna-1,4,9(11),16-tetraene-3,20-dione compound of Formula I, which comprises reacting 21-acetyloxy-pregna-1,3,5,9(11),16-pentaene-3-oxo acetate with a fluorinating agent.

  提供了一种制备Formula I中的21-乙酰氧基-6-α-氟孕甾-1,4,9(11),16-四烯-3,20-二酮化合物的过程，该过程包括将21-乙酰氧基-孕甾-1,3,5,9(11),16-五烯-3-酮醋酸酯与氟化剂反应。
• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR LE TRAITEMENT D'UNE INFLAMMATION
  申请人：RESOLVYX PHARMACEUTICALS INC

  公开号：WO2010120719A1

  公开（公告）日：2010-10-21

  The invention relates to novel resolvin compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel resolvin compounds of the invention.

  这项发明涉及新型利用新型resolvin化合物和其药物制剂的治疗方法。
• [EN] THERAPEUTIC COMPOUNDS<br/>[FR] COMPOSÉS THÉRAPEUTIQUES
  申请人：RESOLVYX PHARMACEUTICALS INC

  公开号：WO2010039531A1

  公开（公告）日：2010-04-08

  The invention relates to novel resolvin compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel resolvin compounds of the invention.

  这项发明涉及新型resolvin化合物及其制药制剂。该发明还涉及使用该发明的新型resolvin化合物进行治疗的方法。
• Stable Corticosteroid Nanoparticulate Formulations and Methods for the Making and Use thereof
  申请人：MARINUS PHARMACEUTICALS

  公开号：US20130243830A1

  公开（公告）日：2013-09-19

  Disclosed are stable corticosteroid nanoparticulate formulations, methods of making and therapeutic uses thereof.

  公开了稳定的类固醇纳米粒子配方、制备方法及其治疗用途。
• Stable Corticosteroid Nanoparticulate Formulations And Methods For The Making And Use Thereof
  申请人：Shaw Kenneth

  公开号：US20110008453A1

  公开（公告）日：2011-01-13

  Disclosed are stable corticosteroid nanoparticulate formulations, methods of making and therapeutic uses thereof.

  本发明揭示了稳定的皮质类固醇纳米粒子制剂，其制备方法和治疗用途。